您当前的位置: 首页 > 资源详情

Prnewswire,1月17日,Menarini Diagnostics CoronaMeltVAR Real-Time PCR kit simultaneously detects SARS CoV-2 and identifies the Omicron Variant

编译者:YUTING发布时间:2022-2-8点击量:56 来源栏目:最新研究

FLORENCE, Italy, Jan. 17, 2022 /PRNewswire/ -- The new Omicron variant is spreading rapidly causing an increase in infections at unprecedented speed. On November 28th, WHO officially recommended laboratories to use Real Time PCR detection kits capable of identifying putative Omicron variant infections, directly at the moment of the positivity test.

To support this recommendation, Menarini offers CoronaMeltVAR, a CE-IVD Real-Time PCR kit based on intercalating dye and melting curve analysis. The kit detects positive samples with high sensitivity, through the amplification of two targets, both compatible with all variants and with the wild type form, simultaneously revealing with distinct signals the suspect presence of Omicron Variant BA.1, BA.2, as well as Alpha, Beta/Gamma and WT/Delta.

All responses are obtained in a single run on each sample, with no loss of sensitivity compared to normal kits and without the need to perform a second reflex test on positive samples. The kit is compatible with most RNA extraction protocols and Real-Time PCR instruments capable of performing melting curve analysis at moderate resolution. CoronaMeltVAR provides SARS CoV-2 CE IVD detection and Omicron surveillance in less than 2 hours.

"We are extremely proud to have made this unique solution available so quickly. It is helping healthcare professionals in providing a specific, rapid and accurate solution for the diagnosis and identification of Covid-19 Omicron variant," said Fabio Piazzalunga, General Manager & Global Head of A.Menarini Diagnostics and Chairman/CEO of Menarini Silicon Biosystems.

A.Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world.

A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2020 turnover of € 3.750 billion.

www.menarinidiagnostics.com

Logo: https://mma.prnewswire.com/media/1584634/Menarini_Logo.jpg

SOURCE Menarini Industrie Farmaceutiche Riunite

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 Phys.org,2月21日,Why natural killer cells react to COVID-19
  2. 2 ScienceDaily,2月18日,T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer
  3. 3 2月18日_研究发现伊维菌素对轻度至中度COVID-19无效
  4. 4 2月17日_抗磷脂自身抗体可使COVID-19患者出现血栓
  5. 5 2月21日_科学家合成SARS-CoV-2病毒颗粒并发现刺突蛋白的转换机制
  6. 6 2月16日_免疫细胞靶向的SARS-CoV-2蛋白会引发蝙蝠冠状病毒的反应
  7. 7 Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19
  8. 8 Medicalxpress,2月16日,Study suggests increased risk of mental health disorders after COVID-19 infection
  9. 9 2月17日_高水平雌激素和抗酸剂可降低COVID-19风险
  10. 10 2月17日_研究发现COVID-19疫苗可提供持久的保护以预防再感染

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190